Cu-64, Ga-68, and F-18 radioisotopes are used in majority of the targeted PET radiotracers, and each offers trade-offs between image resolution, logistical convenience, cost and diagnostic versatility. The table below
The field of targeted nuclear medicine is rapidly evolving as new players and innovative therapies enter the space. Two Lu-177 targeted radiotherapies are currently marketed from Novartis, for Prostate Cancer
ITM Isotope Technologies Munich (ITM), announced on Nov. 13 that the U.S. FDA has accepted the company’s NDA for n.c.a. 177Lu-edotreotide (ITM-11, 177Lu-edotreotide), a targeted radiotherapeutic investigational agent for the treatment of
Coronary artery disease (CAD) is a leading cause of death worldwide, and requires precise, accessible, and versatile diagnostic imaging agents. Myocardial perfusion imaging (MPI) plays a central role in evaluating
Several leading companies in the nuclear medicine targeted imaging space have seen their stock valuations decline in recent quarter, despite continued clinical progress. Stock prices of companies like Lantheus Holdings,
Introduction Current oncology radiopharmaceutical therapies rely on a single biomarker target to deliver cytotoxic radiation to tumors. However, tumor heterogeneity and receptor variability often limit efficacy of these radiotherapeutics. Dual-biomarker
On August 11, 2025, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) introduced the “Global Radiopharmaceutical Clinical Trials Finder”, an AI-supported platform designed to make patient enrollment in nuclear
In the competitive world of PET imaging modality, copper-64 (Cu-64) tracers are emerging as a compromise between the tracers from two commercial isotopes gallium-68 (Ga-68) and fluorine-18 (F-18). Leveraging their
Introduction Mayo Clinic dosed the first patient last week with Ac-225-DOTATATE radiotherapeutic (RYZ101), an alpha-emitter, by RayzeBio (a BMS company), for metastatic, estrogen receptor–positive (ER⁺), human epidermal growth factor receptor
Introduction Ac-225 is an α-emitting radionuclide with a half-life of 9.9 days. Its high energy, multi-day half-life and short travel distance in tissues makes it an attractive radioisotope for targeted
Cu-64, Ga-68, and F-18 radioisotopes are used in majority of the targeted PET radiotracers, and each offers trade-offs between image resolution, logistical convenience, cost and diagnostic versatility. The table below
The field of targeted nuclear medicine is rapidly evolving as new players and innovative therapies enter the space. Two Lu-177 targeted radiotherapies are currently marketed from Novartis, for Prostate Cancer
ITM Isotope Technologies Munich (ITM), announced on Nov. 13 that the U.S. FDA has accepted the company’s NDA for n.c.a. 177Lu-edotreotide (ITM-11, 177Lu-edotreotide), a targeted radiotherapeutic investigational agent for the treatment of
Coronary artery disease (CAD) is a leading cause of death worldwide, and requires precise, accessible, and versatile diagnostic imaging agents. Myocardial perfusion imaging (MPI) plays a central role in evaluating
Several leading companies in the nuclear medicine targeted imaging space have seen their stock valuations decline in recent quarter, despite continued clinical progress. Stock prices of companies like Lantheus Holdings,
Introduction Current oncology radiopharmaceutical therapies rely on a single biomarker target to deliver cytotoxic radiation to tumors. However, tumor heterogeneity and receptor variability often limit efficacy of these radiotherapeutics. Dual-biomarker
On August 11, 2025, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) introduced the “Global Radiopharmaceutical Clinical Trials Finder”, an AI-supported platform designed to make patient enrollment in nuclear
In the competitive world of PET imaging modality, copper-64 (Cu-64) tracers are emerging as a compromise between the tracers from two commercial isotopes gallium-68 (Ga-68) and fluorine-18 (F-18). Leveraging their
Introduction Mayo Clinic dosed the first patient last week with Ac-225-DOTATATE radiotherapeutic (RYZ101), an alpha-emitter, by RayzeBio (a BMS company), for metastatic, estrogen receptor–positive (ER⁺), human epidermal growth factor receptor
Introduction Ac-225 is an α-emitting radionuclide with a half-life of 9.9 days. Its high energy, multi-day half-life and short travel distance in tissues makes it an attractive radioisotope for targeted
“Supply Chain Logistics For A PET Radiotracer Manufacture”
Supply chain for an 18F radioisotope based PET radiotracer manufacture is discussed in detail along with brief manufacturing descriptions provided for context. A critical report for supply chain, manufacturing, business and investing personnel to familiarize with the basics of supply chain for this category of high application, commercially critical PET diagnostic imaging agents.
Click the icon below to download the eReport.
